Detecting Hypertension Signs with Wearable Sensors

Google Research presents an AI system using smartwatch sensors to passively detect hypertension signs without cuff calibration. Validated against clinical gold standards, the tool aggregates PPG and accelerometer data to identify persistent hypertensive states, offering a scalable screening method for high blood pressure awareness.

Audio reading is not available in this browser
Detecting Hypertension Signs with Wearable Sensors

Tags

Quick summary

Google Research presents an AI system using smartwatch sensors to passively detect hypertension signs without cuff calibration. Validated against clinical gold standards, the tool aggregates PPG and accelerometer data to identify persistent hypertensive states, offering a scalable screening method for high blood pressure awareness.

Detecting Hypertension Signs with Wearable Sensors

Hypertension, frequently referred to as the "silent killer," affects over one billion people globally. A significant portion of these individuals remain unaware of their condition because high blood pressure (BP) rarely presents with obvious symptoms. Consequently, diagnosis typically occurs only through incidental screening. This gap in awareness is particularly acute among younger adults aged 18 to 44, where missed diagnoses can delay life-saving early interventions and increase the long-term risk of adverse cardiovascular events such as stroke or heart failure.

While office-based blood pressure measurement serves as the primary initial screening gateway, recent years have seen the emergence of cuffless wearable devices as potential tools to complement episodic office care. However, existing commercial solutions often require regular calibration using a traditional arm cuff. This dependency means they generally track relative changes from a baseline cuff reading rather than identifying absolute hypertensive states, which limits their utility as independent screening tools.

To address these limitations, Google Research has developed a new multimodal artificial intelligence (AI) system capable of passively detecting signs of hypertension using a consumer smartwatch without requiring any cuff calibration. Dubbed AI-PPG-ACC-HTN, this system was validated against the clinical gold standard of 24-hour ambulatory blood pressure monitoring (ABPM). According to the publisher, the system achieves accuracy levels comparable to traditional cuff-based diagnostic workflows for both initial and confirmatory screening. These research findings helped inform the blood pressure trends Health Guardian feature in the Google Health app.

How the System Works

Instead of attempting to estimate exact, point-in-time systolic and diastolic blood pressure values—which are highly susceptible to transient environmental noise—the system reframes the problem. It focuses on identifying an individual's underlying, persistent hypertensive state by aggregating passive physiological signatures over multiple days.

The system leverages data from two sensors already active on modern smartwatches:

  • Photoplethysmography (PPG): An optical sensor that tracks changes in blood volume at the wrist by measuring reflected light that captures pulse wave contours.
  • Accelerometry (ACC): A motion sensor that identifies periods of stillness and captures the ballistocardiogram (BCG), the subtle physical vibrations of the wrist caused by the mechanical ejection of blood from the heart into the aorta.

The AI system uses PPG and accelerometer (ACC) signals recorded using a consumer smartwatch to create waveform embeddings. These embeddings are aggregated over time (days) into a person-level embedding. Along with a user's height, which serves as a reliable proxy for arterial path length, this aggregated data is used to predict their blood pressure status.

To build this system, the researchers employed a two-stage machine learning approach:

Stage 1: Self-supervised Pre-training (The Waveform Encoder)

The team trained a 1-D deep convolutional neural network using self-supervised contrastive learning. By analyzing a large, unlabeled dataset of 492,347 hours of sensor data from 2,109 consenting participants, the model learned to map overlapping 15-second PPG and ACC waveforms from the same individual close together in a latent space. This process allowed the model to discover complex, physiologically rich features of vascular and mechanical cardiac function without requiring manual feature engineering or medical labels.

Stage 2: Person-level Aggregation & Classification

For each user, these 15-second feature blocks (embeddings) are mean-aggregated across multiple days of wear to wash out ephemeral noise like sudden movements or temperature changes. Finally, the individual's aggregated embedding is combined with their height and fed into a regularized logistic regression classifier to calculate a continuous hypertension probability score.

Rigorous Validation Against the Clinical Gold Standard

To evaluate the system, Google Research conducted a prospective, multi-center clinical study across five US sites involving 196 consenting diverse participants. These participants were free from known cardiovascular disease and were not taking blood pressure medications.

Importantly, the study benchmarked the smartwatch's performance against 24-hour ambulatory blood pressure monitoring (ABPM), the clinical gold standard for hypertension diagnosis. The evaluation covered two distinct clinical use case scenarios: initial screening and confirmatory testing.

Scenario 1: Initial Screening

In the initial screening phase, the smartwatch achieved a moderate sensitivity of 65.8% and a high specificity of 90.0%. This resulted in a high positive predictive value (PPV) of 80.6%. In comparison, initial office-based screenings showed a sensitivity of 55.3% and a moderate PPV of 77.8% when benchmarked against the gold standard.

Scenario 2: Confirmatory Testing

For individuals who initially screen positive for high blood pressure in a clinic, current guidelines recommend confirmatory out-of-office tracking. The study examined the subset of participants (N=48) who had elevated initial office BP to see how well the smartwatch could confirm sustained hypertension.

The multimodal system achieved a moderate sensitivity of 78.4%, a high specificity of 90.9%, and a high PPV of 96.7%. In comparison, the performance of return office BP measurements showed lower point estimates of sensitivity (67.6%), specificity (63.6%), and PPV (86.2%). Furthermore, the smartwatch approach proved competitive with multi-day home monitoring, which yielded a sensitivity of 89.2%, specificity of 81.8%, and a PPV of 94.3%.

Taken together, the results show that the system can detect hypertension with accuracy levels comparable to traditional cuffed BP devices within the existing clinical framework.

Model Interpretability

To gain an understanding of what the AI model may be paying attention to, researchers visualized the average pulse waveforms from users with the highest and lowest predicted probabilities of hypertension. The analysis revealed several key physiological indicators:

  • Reduced Pulse Width: Waveforms linked to a higher risk of hypertension exhibited a slightly narrower pulse width, indicating a smaller change in blood volume. This may suggest stiffer arteries that are less able to expand.
  • Pulse Wave Reflection: Higher AI risk scores correlated with a slower systolic upstroke (the initial surge of blood) and a lower d/a ratio. This specific metric compares the initial forward-traveling pulse wave to the reflected wave bouncing back from the body's vascular network.
  • Mechanical Heart Vibrations: The smartwatch accelerometer successfully captured the ballistocardiogram (BCG) signal. In users with higher predicted hypertension, researchers observed distinct physical modulations in these micro-vibrations, specifically deeper "K waves" and wider "IJK complexes."

Outlook and Limitations

Smartwatch-based hypertension screening is not intended to replace standard clinical arm cuffs or provide a definitive standalone medical diagnosis. Instead, this research points to the potential for a highly scalable, passive tool for opportunistic screening.

This work represents early feasibility research and methodologies described here are purely exploratory and are not indicative of any existing or upcoming commercial product feature or device capability. By gently prompting at-risk individuals to step into a clinic for formal assessment, this technology holds the potential to significantly close the global awareness gap and catch hypertension before it causes permanent cardiovascular damage.

The research was a collaborative effort between Google Research, Beth Israel Deaconess Medical Center, and Harvard Medical School.

Source:

  • Detecting signs of hypertension using wearable sensors — Google Research — https://research.google/blog/detecting-signs-of-hypertension-using-wearable-sensors

Sources